New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO)
Halozyme Therapeutics (HALO) reported strong first-quarter 2026 results, including revenue of US$376.71 million and net income of US$150.05 million. The company also announced a new US$1.00 billion share repurchase authorization and a significant global collaboration with GSK to use its ENHANZE technology for oncology targets. These developments, particularly the GSK deal, are expected to broaden Halozyme's revenue streams beyond its current key partners and may reshape its investment narrative.
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO)
Halozyme Therapeutics (HALO) recently reported strong Q1 2026 results, reaffirmed revenue guidance, and announced a new share repurchase program of up to $1 billion. Additionally, a new global collaboration with GSK for its ENHANZE technology in oncology could diversify Halozyme's revenue streams and reduce reliance on its current major partners while reinforcing the role of subcutaneous drug delivery in cancer care. These developments could reshape the investment narrative for Halozyme, despite existing risks related to partner concentration and intellectual property.
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
This article provides an analysis of Halozyme Therapeutics' (HALO) Q1 earnings, highlighting that the company surpassed both revenue and earnings per share estimates. Investors reacted positively to the news, driving the stock price up. The report likely delves into the key factors contributing to this strong financial performance and the outlook for the company.
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Halozyme Therapeutics reported strong Q1 2026 results, surpassing analyst estimates for revenue, adjusted EPS, and adjusted EBITDA, driven by significant royalty revenue growth from its ENHANZE technology. The company reconfirmed its full-year guidance and highlighted key product adoptions. Analysts focused on future contributors from ENHANZE products, Hypercon technology's scalability and manufacturing, and the impact of milestones and share buybacks on guidance.
Halozyme Therapeutics Q1 2026 Earnings Review | HALO Stock - News and Statistics
Halozyme Therapeutics (NASDAQ:HALO) reported strong first-quarter 2026 results, with revenues surging 42.2% to $376.7 million, surpassing analyst expectations. The company announced a new $1 billion share repurchase program and projected at least $400 million in repurchases for 2026. Halozyme also highlighted three new collaboration and licensing agreements, demonstrating strong interest in its Hypercon and ENHANZE platforms.
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO
Arbejdsmarkedets Tillaegspension (ATP) recently acquired a new position in Halozyme Therapeutics (NASDAQ:HALO), purchasing 375,933 shares valued at approximately $25.3 million, making it ATP's third-largest holding. This investment comes as Halozyme reported strong quarterly earnings, beating revenue and EPS estimates and raising its FY 2026 guidance. Despite insider selling activity, analysts maintain a "Moderate Buy" consensus rating with an average target price of $80.67 for the biopharmaceutical company.
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares
Morgan Stanley Smith Barney LLC has filed a Form 144 notice to sell 14,700 shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO). The shares stem from three restricted stock vesting events that occurred between February 16, 2026, and February 23, 2026. A Form 144 is a regulatory document indicating an intent to sell restricted securities, not a confirmation of an actual sale.
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback
Halozyme Therapeutics (HALO) reported strong Q1 2026 earnings, reaffirming full-year guidance and announcing a US$1 billion share repurchase program. The company also secured a new global collaboration for its ENHANZE drug delivery platform with GSK. Despite recent share price fluctuations, analysts suggest Halozyme is undervalued at around US$85.78, with its ENHANZE platform benefiting from the shift towards subcutaneous drug delivery, but its P/E ratio is higher than industry averages.
Halozyme (NASDAQ: HALO) posts 42% Q1 revenue growth and unveils new $1B share repurchase plan
Halozyme (NASDAQ: HALO) reported robust Q1 2026 financial results, with total revenue increasing 42% year-over-year to $376.7 million and royalty revenue growing 43%. The company announced a new $1 billion share repurchase program, projecting at least $400 million in buybacks for 2026, and reaffirmed its strong full-year 2026 guidance, including total revenue of $1.71–$1.81 billion and non-GAAP EPS of $7.75–$8.25. New collaboration and licensing agreements with GSK, Vertex, and Oruka are expected to further strengthen its future royalty pipeline.
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative
Halozyme Therapeutics reported strong Q1 2026 results with US$376.7 million in revenue and US$1.27 basic EPS, challenging the bearish narrative of margin compression following a one-off loss in Q4 2025. The company's net income rebounded to US$150.0 million, demonstrating a quick return to profitability despite previous volatility. While analysts forecast moderate growth and the stock trades at a 24.1x P/E, a discounted cash flow analysis suggests a much higher fair value, sparking debate between bullish and bearish outlooks on its ENHANZE platform.
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback
Halozyme Therapeutics (HALO) reported a strong Q1 2026 with significant year-over-year growth, reaffirming full-year guidance and announcing a US$1 billion share repurchase program. The company also secured a new collaboration with GSK for its ENHANZE drug delivery platform. Despite recent short-term share price fluctuations, analysts project a fair value of around $85.78 per share, suggesting the stock is currently undervalued at $70.03, though its P/E ratio is higher than industry averages.
Halozyme CEO Helen Torley sells $3.43m in stock
Halozyme Therapeutics CEO Helen Torley recently sold approximately $3.43 million worth of company stock over three days in May 2026, under a pre-arranged trading plan. Concurrently, she acquired 50,000 shares through exercised stock options. These transactions follow strong Q1 2026 financial results for Halozyme, which exceeded analyst expectations for both EPS and revenue.
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan
Halozyme Therapeutics, Inc. CEO Helen Torley exercised options to acquire 50,000 shares of common stock at $12.07 per share and simultaneously sold 50,000 shares in open-market trades at prices ranging from the mid-$60s to low-$70s. These transactions, which occurred between May 11-13, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025. Following these sales, Torley directly holds 777,780 shares of common stock and retains vested options for an additional 51,923 shares.
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative
Halozyme Therapeutics reported a Q1 2026 EPS of US$1.27 and revenue of US$376.7 million, marking a rebound after a Q4 2025 loss. This performance challenges the bearish narrative of consistent margin compression and dependence on the ENHANZE platform, though some volatility and patent risks remain. The company's valuation, with a trailing P/E of 24.1x and a DCF fair value significantly higher than its current share price, presents a mixed picture for investors.
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
This article provides a Q1 recap for therapeutics stocks, focusing on Halozyme Therapeutics (HALO) and its peers. It details HALO's strong revenue beat and new share repurchase program, while also highlighting Moderna (MRNA) as the best performer and United Therapeutics (UTHR) as the weakest. The report analyzes the financial performance of each company and discusses industry tailwinds and headwinds.
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Therapeutics (NASDAQ:HALO) announced a global collaboration and license agreement with GSK, granting GSK rights to Halozyme’s ENHANZE® drug delivery technology for oncology targets including antibody-drug conjugates (ADCs). GSK will make an upfront payment, potential milestone payments, and royalties to Halozyme. H.C. Wainwright also raised Halozyme's price target to $95 from $90, maintaining a Buy rating.
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and …
Halozyme Therapeutics (HALO) saw its shares jump 8.1% after reporting record revenue growth in its first quarter 2026 earnings. The biotechnology company closed at $71.82 on Tuesday, May 12, 2026, driven by strong top-line execution and investor confidence in its growth trajectory. The market reacted positively to the record revenue, signaling the critical role of top-line momentum for biotechnology companies with platform technologies like Halozyme's ENHANZE.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported strong Q1 2026 earnings, exceeding expectations with an EPS of $1.60. The company reaffirmed its full-year 2026 and 2026-2028 financial guidance, projecting ENHANZE royalties to surpass $1 billion for the first time in 2026. Halozyme also announced a new $1 billion share buyback authorization, emphasizing capital allocation for reinvestment, share repurchases, debt reduction, and evaluating drug delivery M&A opportunities, while expanding its ENHANZE and Hypercon technologies through new collaborations and pipeline advancements.
Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q1 Revenue $376.7M, Vs. FactSet Est of $358.6M
Halozyme Therapeutics, Inc. (HALO) reported robust Q1 revenue of $376.7 million, significantly surpassing the FactSet estimate of $358.6 million. This strong financial performance indicates a positive quarter for the pharmaceutical company.
Halozyme Therapeutics, Inc. Profit Rises In Q1
Halozyme Therapeutics, Inc. reported a significant increase in its Q1 profit and revenue compared to the previous year. The company's net income rose to $150.04 million, or $1.22 per share, with adjusted earnings of $194.29 million, or $1.60 per share. Revenue increased by 42.2% to $376.70 million, and the company provided full-year EPS guidance of $7.75 to $8.25 and revenue guidance of $1.710 billion to $1.810 billion.
Halozyme Therapeutics: Q1 Earnings Snapshot
Halozyme Therapeutics Inc. (HALO) reported strong first-quarter results, with profits of $150 million, or $1.22 per share, surpassing Wall Street expectations. Adjusted earnings per share reached $1.60, higher than the average analyst estimate of $1.54. The biopharmaceutical company also exceeded revenue forecasts, posting $376.7 million against an expected $357.7 million.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
H.C. Wainwright has reiterated its Buy recommendation and raised its price target for Halozyme Therapeutics (HALO) to $95 from $90, anticipating stronger royalty growth through 2026. This optimism follows a recent exclusive partnership between Halozyme and Oruka Therapeutics for Hypercon technology, which includes an upfront payment and potential future milestones and royalties for HALO. Halozyme, a San Diego-based biotechnology company, specializes in oncology drug delivery through its ENHANZE technology.
Earnings Flash (HALO) Halozyme Therapeutics, Inc. Reports Q1 Revenue $376.7M, vs. FactSet Est of $358.6M
Halozyme Therapeutics, Inc. reported its Q1 revenue reached $376.7 million, surpassing the FactSet estimate of $358.6 million. The company also announced Q1 adjusted EPS of $1.60, exceeding the estimated $1.55. Additionally, Halozyme expects its full-year 2026 revenue to be between $1.71 billion and $1.81 billion, with adjusted EPS in the range of $7.75 to $8.25.
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics reported strong first-quarter 2026 financial results, with total revenue up 42% year-over-year to $377 million and royalty revenue increasing by 43% to $241 million. The company also announced a new $1 billion share repurchase program, planning to buy back at least $400 million in 2026, and reaffirmed its full-year 2026 financial guidance, projecting significant growth in total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS. Key highlights include new collaboration agreements with Vertex, Oruka, and GSK for its ENHANZE and Hypercon technologies, and FDA approval for VYVGART Hytrulo in generalized myasthenia gravis, expanding its market opportunities.
How Halozyme’s ENHANZE ADC Deal with GSK Could Reshape Halozyme Therapeutics (HALO) Investors’ Outlook
Halozyme Therapeutics recently secured a global collaboration and license agreement with GSK for its ENHANZE drug delivery technology, specifically for subcutaneous versions of oncology targets including antibody drug conjugates. This deal, Halozyme's first ENHANZE partnership involving ADCs, is expected to broaden the technology's application in cancer therapies and diversify future royalty streams. The partnership could reinforce bullish analyst forecasts for Halozyme's revenue and earnings, though the company still faces risks related to partner launch execution and legal/pricing headwinds.
10 Best Healthcare Stocks to Buy for the Long Term
This article identifies Halozyme Therapeutics, Inc. (NASDAQ:HALO) as one of the best healthcare stocks for long-term investment, noting its recent collaboration with GSK for its ENHANZE® drug delivery technology in oncology. The collaboration involves upfront payments, future milestones, and royalties for Halozyme, while H.C. Wainwright recently raised Halozyme's price target to $95. Halozyme is recognized for its biopharmaceutical technology platform developing drug-device combination products that enhance patient comfort and adherence.
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript
This article provides the transcript of Halozyme Therapeutics Inc.'s presentation at the Leerink Global Healthcare Conference on March 10, 2026. CEO Helen Torley discusses the company's recent progress, particularly focusing on the acquisitions of Electrify and Surf Bio, which are expected to drive long-term growth. The transcript initiates a conversation about these strategic moves and their implications for Halozyme's future.
Number of shareholders of Halozyme Therapeutics, Inc. – NASDAQ:HALO
This article provides details on the number of shareholders for Halozyme Therapeutics, Inc. (NASDAQ: HALO). It highlights that the information is presented without specific period values or changes. The content is primarily a placeholder for financial data related to shareholder numbers within the TradingView platform.
Halozyme Therapeutics Inc expected to post earnings of $1.53 a share - Earnings Preview
Halozyme Therapeutics Inc (HALO) is expected to announce earnings of $1.53 per share. This information comes from a Reuters earnings preview. The article provides financial data sourced from Refinitiv, indicating an upcoming earnings report for the company.
Number of shareholders of Halozyme Therapeutics, Inc. – GETTEX:RV7
This article provides information on the number of shareholders for Halozyme Therapeutics, Inc., under the GETTEX:RV7 ticker. It is a financial data point from TradingView, which aggregates market data from ICE Data Services and reference data from FactSet. The content primarily focuses on the company's financial overview within a trading platform context.
Deal Watch: GSK Calls On Halozyme’s Enhanze In Cancer ADC Administration
GSK has partnered with Halozyme for their Enhanze technology, specifically for cancer ADC administration. This collaboration aims to leverage Halozyme's drug delivery platform to improve the administration of GSK's antibody-drug conjugates. The article is part of a weekly "Deal Watch" bulletin from Scrip, focusing on significant pharma business news.
A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price Swings
Halozyme Therapeutics (HALO) has experienced recent stock volatility, with a 5% monthly gain and a 15% decline over three months, yet a three-year return of 92.37%. Despite its current trading price of $66.35, analysts suggest it is 23% undervalued with a fair value of $85.78, driven by its ENHANZE drug delivery platform. However, its P/E ratio of 24.8x is higher than the industry average, indicating potential risk if growth expectations are not met.
Psoriasis Data, Halozyme Pact and Equity Raise Might Change The Case For Investing In Oruka Therapeutics (ORKA)
Oruka Therapeutics recently reported positive interim Phase 2a data for its psoriasis drug ORKA-001, secured a substantial equity offering, and partnered with Halozyme Therapeutics for drug delivery. These developments strengthen the investment narrative for ORKA, suggesting ORKA-001 could become a more convenient biologic option, backed by significant capital for development. However, investors face risks including dilution, upcoming lock-up expiry, and trial execution challenges, alongside a widely varying fair value estimates from analysts.
Halozyme Therapeutics (HALO) director receives RSUs and options grant
Halozyme Therapeutics director James Paul Lang received an annual grant of 3,796 restricted stock units (RSUs) and options to purchase 6,040 shares of common stock, as part of the company's director compensation program. The RSUs and options will vest on the earlier of May 5, 2027, or the next annual stockholder meeting, with RSU settlement deferred until the completion of his board service. His direct common stock holdings now total 4,685 shares and he beneficially owns 6,040 derivative shares.
Halozyme Stockholders Back Board, Pay and Auditor Choices
Halozyme Therapeutics, Inc. stockholders re-elected two Class I directors, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year at their recent Annual Meeting. These voting outcomes demonstrate continued shareholder support for the company's current governance, compensation practices, and financial oversight. An analyst rating on HALO stock is a Buy with a $95.00 price target, and TipRanks' AI Analyst, Spark, rates HALO as Outperform due to strong financial performance, despite weak technical momentum.
Halozyme (HALO) director awarded RSUs and options in annual equity grants
Halozyme Therapeutics director Barbara Gayle Duncan received 3,796 restricted stock units (RSUs) and an option to purchase 6,040 shares of common stock as part of the company's annual director compensation program. These equity grants will vest on the earlier of May 5, 2027, or the date of the next annual stockholders meeting. Following these transactions, Duncan directly holds 23,715 common shares, and the stock option has an exercise price of $65.87 per share and an expiration date of May 5, 2036.
HALOZYME THERAPEUTICS, INC. Insider Trading Activity
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation including 6,796 restricted stock units (RSUs) and a stock option for 6,040 shares at an exercise price of $65.87. Both the RSUs and options granted on May 5, 2026, will vest on the earlier of May 5, 2027, or the company's next annual meeting of stockholders. This transaction, categorized as neutral by analysts, represents routine director compensation aimed at aligning her interests with shareholders.
Halozyme (NASDAQ: HALO) shareholders approve directors, pay plan and Ernst & Young
Halozyme Therapeutics, Inc. shareholders approved all three proposals at their Annual Meeting held on May 5, 2026. This included re-electing Bernadette Connaughton and Matthew L. Posard as Class I directors, giving advisory approval to the compensation of named executive officers, and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A large majority of shareholders participated, with 104,138,244 shares represented out of 118,474,300 outstanding common shares.
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates (ADCs), utilizing Halozyme's ENHANZE drug delivery technology. This marks Halozyme's first ENHANZE agreement to include ADC targets and includes an option for additional future targets, with the first clinical trial projected to begin in 2026. Halozyme will receive an upfront payment, potential future milestone payments, and royalties on net sales of products incorporating ENHANZE.
Bokf Na Takes Position in Halozyme Therapeutics, Inc. $HALO
Bokf Na has initiated a new position in Halozyme Therapeutics (NASDAQ:HALO) during the fourth quarter, acquiring 16,050 shares valued at approximately $1.08 million. This move is part of broader institutional activity, with hedge funds and other institutional investors holding 97.79% of the stock. Despite a consensus "Hold" rating and a target price of $79.11, some analysts have recently increased their price targets for the biopharmaceutical company.
Halozyme Agrees to License Hypercon Technology to Oruka to Develop Psoriasis Treatment
Halozyme's wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka Therapeutics. This agreement allows Oruka to use Halozyme's Hypercon technology to develop ORKA-001 for psoriasis treatment, with potential expansion for an additional target. The Hypercon technology enables hyperconcentration of drugs, reducing injection volume and improving patient convenience, aligning with Oruka's mission to develop patient-friendly treatments for chronic skin diseases.
Halozyme licenses Hypercon technology to Oruka for psoriasis drug
Halozyme Therapeutics has licensed its Hypercon microparticle technology to Oruka Therapeutics for use in ORKA-001, a drug being developed for psoriasis and related inflammatory diseases. This agreement strengthens Halozyme's position as a drug delivery technology provider and includes an upfront payment and future milestone payments to Halozyme, along with mid-single digit royalties on net sales. The deal highlights Halozyme's growing portfolio of collaborations and its strong financial health, with analysts reiterating Buy ratings and price targets for the company.
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Halozyme Therapeutics and Oruka Therapeutics have announced a global collaboration and license agreement. Oruka will use Halozyme's Hypercon™ technology for ORKA-001, a drug in development for psoriasis, as well as one additional target. This partnership highlights the broad applicability of Hypercon™, a microparticle technology designed to reduce injection volume and improve patient convenience for highly concentrated drugs.
Halozyme director Bernadette Connaughton sells $103,155 in stock
Halozyme Therapeutics director Bernadette Connaughton sold 1,625 shares of common stock for $103,155 on May 1, 2026, under a pre-arranged trading plan, leaving her with 38,498 shares. InvestingPro analysis suggests the stock is undervalued, leading to aggressive share buybacks by management. The company has seen its price target raised by H.C. Wainwright and TD Cowen due to strong financial performance and projected royalty growth.
HALOZYME (NASDAQ: HALO) director sells 1,625 shares in Rule 10b5-1 trade
HALOZYME (NASDAQ: HALO) director Bernadette Connaughton sold 1,625 shares of common stock for $63.48 per share, totaling $103,155. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than being an opportunistic sale. After the sale, Connaughton retains 38,498 shares, suggesting a routine liquidity move and not a significant change in her investment thesis.
The Bull Case For Halozyme Therapeutics (HALO) Could Change Following Ex-J&J CFO Hire – Learn Why
Halozyme Therapeutics, Inc. (HALO) has appointed Darren Snellgrove, former CFO of Johnson & Johnson’s Pharmaceuticals division, as its new Chief Financial Officer, signaling a significant upgrade in financial leadership. This hire is expected to reshape Halozyme's capital allocation and growth strategy, although near-term catalysts still revolve around existing collaborations and upcoming earnings. The company's investment narrative focuses on the success of its ENHANZE drug delivery platform and its ability to maintain high-value partnerships.
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape
Halozyme Therapeutics has adjusted its valuation, showcasing a P/E ratio of 11 and an exceptionally high return on equity of 1371.85%. While experiencing recent stock fluctuations, its long-term performance, especially over ten years, remains strong, outperforming the S&P 500. The company's competitive stance in the biotechnology sector is highlighted by comparisons with peers like Elanco Animal Health and BioMarin Pharmaceutical.
The Bull Case For Halozyme Therapeutics (HALO) Could Change Following Ex-J&J CFO Hire – Learn Why
Halozyme Therapeutics (HALO) recently appointed Darren Snellgrove, former CFO of Johnson & Johnson’s Pharmaceuticals division, as its new Chief Financial Officer. This hire is seen as a significant upgrade to Halozyme's financial leadership, potentially reshaping its capital allocation and growth strategy. While near-term catalysts still focus on existing partnerships and upcoming earnings, the long-term outlook may be influenced by Snellgrove's experience, despite ongoing patent challenges and pricing pressures.
Halozyme Therapeutics, Inc. $HALO Holdings Increased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. significantly increased its stake in Halozyme Therapeutics (NASDAQ:HALO) by 66.7% in the fourth quarter, making it their 10th largest holding. Despite institutional buying, insider selling by key executives and a Q4 EPS miss, analysts maintain a "Hold" rating with an average target price of $79.11. The company, which specializes in drug-delivery technologies, reported a 51.6% increase in revenue year-over-year.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average "Hold" recommendation from twelve brokerages, with an average 12-month target price of $79.11. Recent insider selling includes CEO Helen Torley and COO Cortney Caudill, contributing to 118,857 shares sold by insiders in the last 90 days. The company recently missed EPS estimates in its quarterly results, reporting -$0.24 versus an expected $1.92, despite a 51.6% year-over-year revenue increase.
